CorMedix Shares Climb With Higher 1Q Profit, Sales

Dow Jones

05/15

By Christopher Kuo

CorMedix shares rose after the company reported higher first-quarter profit and revenue.

Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date.

The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share.

Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter.

"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand," said Chief Executive Joseph Todisco. "In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity."

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 14, 2026 14:44 ET (18:44 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2635747065"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635747065\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635747065?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 02:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635747065","market":"nz","top_or_hot":-1,"title":"CorMedix Shares Climb With Higher 1Q Profit, Sales","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  CorMedix shares rose after the company reported higher first-quarter profit and revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date. \n</p>\n<p>\n  The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share. \n</p>\n<p>\n  Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter. \n</p>\n<p>\n  \"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 14:44 ET (18:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Shares Climb With Higher 1Q Profit, Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Shares Climb With Higher 1Q Profit, Sales\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-05-15 02:44</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  CorMedix shares rose after the company reported higher first-quarter profit and revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date. \n</p>\n<p>\n  The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share. \n</p>\n<p>\n  Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter. \n</p>\n<p>\n  \"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 14:44 ET (18:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635747065","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635747065","pubTimestamp":1778784240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"CorMedix shares rose after the company reported higher first-quarter profit and revenue.Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date.The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share.Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter.\"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stag","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc.","BK4007":"制药"},"translate_title":"CorMedix股价上涨，第一季度利润和销售额增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  CorMedix shares rose after the company reported higher first-quarter profit and revenue. \n\n\n  Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date. \n\n\n  The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share. \n\n\n  Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter. \n\n\n  \"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity.\" \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 14:44 ET (18:44 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}